Now, the Lundquist Institute (TLI) and Vitalex Biosciences announce that they will move forward in the development of the second-generation fungal vaccine candidate known as VXV‑01—up to and including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback